Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of IV Iron Replacement on Exercise Capacity in HFrEF
NCT05816265Phase 4Terminated
- Start
- Jan 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ferric carboxymaltose in heart failure (HF), iron deficiency anemia (IDA). Started Jan 2024; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure (HF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05816265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816265.